191 related articles for article (PubMed ID: 38537944)
1. Use of progestogens and the risk of intracranial meningioma: national case-control study.
Roland N; Neumann A; Hoisnard L; Duranteau L; Froelich S; Zureik M; Weill A
BMJ; 2024 Mar; 384():e078078. PubMed ID: 38537944
[TBL] [Abstract][Full Text] [Related]
2. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.
Hoisnard L; Laanani M; Passeri T; Duranteau L; Coste J; Zureik M; Froelich S; Weill A
Eur J Neurol; 2022 Sep; 29(9):2801-2809. PubMed ID: 35621369
[TBL] [Abstract][Full Text] [Related]
3. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
[TBL] [Abstract][Full Text] [Related]
4. Classification and pharmacology of progestins.
Schindler AE; Campagnoli C; Druckmann R; Huber J; Pasqualini JR; Schweppe KW; Thijssen JH
Maturitas; 2008; 61(1-2):171-80. PubMed ID: 19434889
[TBL] [Abstract][Full Text] [Related]
5. Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age.
Cockrum RH; Soo J; Ham SA; Cohen KS; Snow SG
Obstet Gynecol; 2022 Sep; 140(3):477-487. PubMed ID: 35926206
[TBL] [Abstract][Full Text] [Related]
6. Classification and pharmacology of progestins.
Schindler AE; Campagnoli C; Druckmann R; Huber J; Pasqualini JR; Schweppe KW; Thijssen JH
Maturitas; 2003 Dec; 46 Suppl 1():S7-S16. PubMed ID: 14670641
[TBL] [Abstract][Full Text] [Related]
7. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas.
Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP
Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677
[TBL] [Abstract][Full Text] [Related]
8. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
Sangkomkamhang US; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD008994. PubMed ID: 33226133
[TBL] [Abstract][Full Text] [Related]
9. Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.
Glujovsky D; Pesce R; Miguens M; Sueldo C; Ciapponi A
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD013827. PubMed ID: 38032057
[TBL] [Abstract][Full Text] [Related]
10. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
11. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
Hofmeyr GJ; Singata-Madliki M; Batting J; Balakrishna Y; Morroni C
BMC Womens Health; 2024 Mar; 24(1):167. PubMed ID: 38459552
[TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
13. [Meningioma under progestin treatment : what attitude to adopt ?].
Cornu E; Pintiaux A; Reuter G; Kridelka F; Pétrossians P; Potorac I
Rev Med Liege; 2023 Oct; 78(10):550-557. PubMed ID: 37830319
[TBL] [Abstract][Full Text] [Related]
14. Cyclical progestogens for heavy menstrual bleeding.
Bofill Rodriguez M; Lethaby A; Low C; Cameron IT
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD001016. PubMed ID: 31425626
[TBL] [Abstract][Full Text] [Related]
15. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
[TBL] [Abstract][Full Text] [Related]
16. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome.
Graillon T; Boissonneau S; Appay R; Boucekine M; Peyrière H; Meyer M; Farah K; Albarel F; Morange I; Castinetti F; Brue T; Fuentes S; Figarella-Branger D; Cuny T; Dufour H
Neurochirurgie; 2021 Nov; 67(6):556-563. PubMed ID: 33989642
[TBL] [Abstract][Full Text] [Related]
17. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids.
Sangkomkamhang US; Lumbiganon P; Laopaiboon M; Mol BW
Cochrane Database Syst Rev; 2013 Feb; (2):CD008994. PubMed ID: 23450594
[TBL] [Abstract][Full Text] [Related]
18. Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study.
Ruan X; Gu M; Cai G; Zhao Y; Wang L; Li X; Mueck AO
Maturitas; 2019 May; 123():1-8. PubMed ID: 31027671
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and Progesterone Therapy and Meningiomas.
Hage M; Plesa O; Lemaire I; Raffin Sanson ML
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947
[TBL] [Abstract][Full Text] [Related]
20. Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate.
Lundström E; Virijevic I; Söderqvist G
Horm Mol Biol Clin Investig; 2020 Jul; 41(3):. PubMed ID: 32735552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
